Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict dangerous clots and bleeds in heart patients

NCT ID NCT07523880

Knowledge-focused Sponsor: Xueyan Zhao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involves over 12,000 Chinese patients with coronary heart disease who take blood thinners. The goal is to find new biological markers that can better predict who is at risk for dangerous blood clots or major bleeding. Researchers will combine genetic, protein, and imaging data with machine learning to create more accurate risk models. This could help doctors choose safer, more personalized treatments for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 12,154 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with coronary heart disease who are receiving dual antiplatelet therapy after percutaneous coronary intervention. The study includes a retrospective cohort of approximately 10,154 patients with existing baseline and follow-up data and biospecimens, derived from a previously established patient cohort. In addition, a prospective cohort of at least 2,000 newly enrolled patients will be recruited.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy. 3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment. 4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent. For newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures. Exclusion Criteria: For patients from the existing cohort: 1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification. 2. No available blood specimen, or specimen that does not meet testing requirements. For newly enrolled patients: 1. Presence of serious comorbid conditions with life expectancy ≤ 6 months. 2. Conditions that significantly affect study compliance or the ability to complete follow-up. 3. Contraindications to blood sampling.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease Hemorrhage hemorrhagic disease thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding Coronary artery disease (CAD) Thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Central China Cardiovascular Hospital

    RECRUITING

    Zhengzhou, Henan, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, 100037, China

  • General Hospital of Northern Theater Command of Chinese People's Liberation Army

    RECRUITING

    Shenyang, Liaoning, 110016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.